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Abstract 
Background: Preemptive genotyping is a strategy that tests for multiple pharmacogenomic variants 
before a drug is prescribed. Pharmacogenomic information currently appears in 165 FDA-approved drug 
labels, and many medications have FDA boxed warnings and/or available Clinical Pharmacogenetics 
Implementation Consortium (CPIC) guidelines that recommend action, such as selecting a different drug 
or dose, in patients with certain genotypes if the genetic test result was available. However, the 
implementation of established pharmacogenomic guidance is hardly done in clinical practice due to the 
lack of a clear population to genotype. Cardiac catheterization laboratory patients serve as a reasonable 
population due to their multiple comorbidities and increased likelihood of being on genetically 
actionable drugs. The objective of this study was to retrospectively assess the projected number of 
actionable pharmacogenetic-guided interventions that could have resulted with preemptive genotyping 
within a six-month time period for cardiac catheterization laboratory patients. 
Methods: This single-center, retrospective study of an established cohort included 183 patients referred 
for coronary angiography between September 2012 and February 2014 at UNC Hospitals. A list of 20 
drugs with genetically actionable FDA boxed warnings and/or CPIC guidelines was established a priori to 
guide medication collection. For these drugs, the relevant genes are HLA-B, CYP2C19, CYP2D6, CYP2C9, 
SLCO1B1, VKORC1/CYP2C9, and DYPD.  Medication information was collected at discharge and at first 
follow-up. The primary endpoint was the projected number of genotype-guided interventions at 
discharge or first follow-up that could have occurred using published allele frequencies to estimate the 
projected presence of at-risk genotypes. Secondary endpoints included the distribution of total 
interventions by gene in the study population, and the projected annual number of genotype-guided 
interventions at discharge or first follow-up in the UNC catheterization laboratory patient population. 
Results: The study population included 122 patients who had a first follow-up visit within 180 days of the 
catheterization. Patients were on average 63 years old, 57% male, and 73% Caucasian. Comorbidities 
included depression (13.9%), hyperlipidemia (63.9%), and heart failure (17.2%). Approximately 38% of 
patients underwent a percutaneous coronary intervention during the catheterization procedure. The 
most prevalent genetically actionable drugs at discharge or first follow-up were clopidogrel (48.4%), 
antidepressants (20.5%), simvastatin (13.9%), and warfarin (9.0%). Corresponding at risk genotypes of 
interest and projected frequencies were CYP2C19 intermediate or poor metabolizers (28.9%) for 
clopidogrel, CYP2C19 ultra-rapid or poor metabolizers (32.5%) for antidepressants, SLCO1B1 C allele 
carriers (23.6%) for simvastatin, and VKORC1/CYP2C9 sensitive or highly sensitive responders (38.3%) for 
warfarin. The total projected number of genotype-guided interventions at discharge or first follow-up in 
the study population was 32. Distribution of total interventions by gene was as follows: 71.9% CYP2C19, 
12.5% SLCO1B1, 12.5% VKORC1/CYP2C9, and 3.1% CYP2C9. Assuming each intervention is unique to one 
patient, a genotype-guided medication intervention could have been made in 26.2% (32 of 122) of the 
study population within 6 months of their presentation to the cardiac catheterization laboratory. When 
carried out to the annual UNC Catheterization Laboratory population, the total projected number of 
genotype-guided interventions at discharge or first follow-up increased to 565.  
Conclusions: A preemptive genotyping strategy with a multi-gene panel in cardiac catheterization 
laboratory patients would result in genotype-guided interventions in approximately 1 out of every 4 
patients. Almost 30% of interventions involved non-CYP2C19 drugs, suggesting the potential benefit of a 
multiplexed genotyping approach that extends beyond CYP2C19 testing. 
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Introduction 
Genetically guided personalized medicine has become more clinically significant in recent years, and the 
US Food and Drug Administration (FDA) is reflecting these new findings in its drug evaluation and 
approval process. In 2005, the FDA issued a comprehensive pharmacogenomics guidance document 
addressing how and when drug development entities should submit genomic data to the FDA.1 Since 
then, pharmacogenomic information has appeared in 165 FDA-approved drug labels.2 Without taking 
into account oncology drugs, which are oftentimes exceedingly complex to dose and administer, there 
are currently 7 medications with genomic-associated black box warnings, 41 with either published 
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines or FDA label recommendations 
influencing drug dosing and selection, and numerous more categorized as genetically “actionable” with 
implications on adverse drug outcomes such as toxicities, side effects, and therapy failures. Over 30 of 
these medications are listed in the Top 200 Drugs of 2012 article published by Pharmacy Times.3 Despite 
this, genetic information is not routinely obtained and the implementation of genotype-guided drug 
regimens into the standard of care remains a subject of ongoing investigation and debate. Due to the 
substantial impact pharmacogenomics could have on health outcomes, there is an increasing need to 
open new avenues for translating and applying it into clinical practice. 
Traditionally, pharmacogenetic testing is done for genetic variations the affect drug response when 
therapy is initiated for patients.  This approach is reactive in that the decision to order the test is made 
alongside or after the decision to initiate therapy.  Often, genotyping patients retrospectively only 
provides pharmacogenetic information pertinent to the specific drug in question and cannot be applied 
to future therapeutic decisions involving agents affected by different genes.  Furthermore, significant 
barriers currently exist, limiting consistent and widespread adoption in everyday clinical practice.  These 
barriers include cost, and lack of capability or long turnaround times at most institutions. However, 
advances in genetic testing methodologies have allowed a single genetic test to interrogate multiple 
genes simultaneously. This advancement in technology, coupled with its competitive pricing, has the 
potential to shift genotyping decision making from a traditional, reactive strategy to one that is 
proactive. Preemptive genotyping is a strategy that tests for multiple pharmacogenomic variants before 
a drug is prescribed, allowing patient genetic information to be stored for later use. The information 
obtained from this genotyping approach can be particularly beneficial to practitioners when prescribing 
a wide range of current and future medications, especially if these therapies come with boxed warnings 
warranting genetic testing or CPIC and other genome-based dosing guidelines. Importantly, preemptive 
genotyping eliminates barriers associated with turnaround time and allows the clinician to focus on how 
to best implement this data into patient care instead of deciding whether the test should be ordered or 
not. Moreover, the unfamiliarity of this material can create more opportunities for pharmacists in 
contributing to both the therapeutic decision-making and educational process by interpreting and 
relaying pharmacogenomic information to providers and patients. Lastly, preemptive genotyping, unlike 
reactive genotyping, allows for genetic information to be readily available in situations where a clinical 
decision or treatment cannot be deferred. Overall, preemptive genotyping could be an effective method 
of implementing pharmacogenomic data in practice and potentially prevent adverse drug-gene 
interactions and subsequent hospital admissions, which can be costly to patients and providers alike.     
Despite its promising outlook, preemptive genotyping still faces challenges preventing widespread 
adoption. To improve the implementation of preemptive genotyping, it is essential to first identify a 
target population where preemptive genotyping would provide maximum clinical benefit and evaluate 
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its projected impact on drug selection and dosing. Cardiac catheterization laboratory patients may be 
ideal candidates as these individuals often have multiple comorbidities, increasing their likelihood of 
being on or being initiated on multiple pharmacologic therapies in which genetic testing is 
recommended.4 For instance, approximately one-third of these patients will have a stent placement, a 
procedure in which testing for the CYP2C19 genotype is recommended prior to starting the patients on 
the anti-platelet agent, clopidogrel. This is due to the diminished effectiveness of the drug in patients 
with certain loss-of-function polymorphisms of the gene, which can lead to failure of therapy and 
potentially fatal cardiovascular events. Other drugs with pharmacogenomic information their labels 
commonly seen with cardiac catheterization laboratory patients include anti-platelet and anti-
thrombotic agents, beta blockers, anti-depressants, statins, and pain relievers.4 To our knowledge, there 
are no studies currently published evaluating the use of preemptive genotyping in this patient 
population. 
Additionally, it is crucial to determine which parameters would be clinically significant in the 
implementation of an established pharmacogenetic guidance. We defined medications as “genetically 
actionable” if they have an FDA boxed warning and/or available Clinical Pharmacogenetics 
Implementation Consortium (CPIC) guideline that recommend action, such as selecting a different drug 
or dose, in patients with certain genotypes if the genetic test result was available.  
The purpose of this study was to retrospectively assess the projected number of actionable 
pharmacogenetic-guided interventions that could have resulted with preemptive genotyping within a 6 
month time period for cardiac catheterization laboratory patients 
Methods 
Patient population 
This was a single-center, retrospective cohort study of 183 UNC Cardiac Catheterization Laboratory 
patients recruited between September 2012 and February 2014.5 An institutional review board 
approved this study. Patients aged 18-80 years who were referred for coronary angiography and 
consented to participation in a DNA biorepository were included. Patients with one or more of the 
following conditions were excluded: severe concurrent illness, systemic inflammatory disease, 
malignancy actively being treated, ST-elevation myocardial infarction (STEMI), end-stage liver disease 
(ESRD) with or without dialysis, systemic immunosuppressive medication use, hematological disorder 
affecting platelet function, prior heart transplantation, hematocrit <30%, and pregnancy. 
Medication selection 
A literature and database review of the Food and Drug Administration’s Table of Pharmacogenomic 
Biomarkers in Drug Labeling and PharmGKB was conducted. Drugs with pharmacogenomic information 
in their FDA labeling were documented (see Table 7). Oncology, immunomodulary, and specialty drugs 
such as ivacaftor were not evaluated due to the biorepository exclusion criteria. The list was 
subsequently narrowed down to only include drugs with actionable pharmacogenomic 
recommendations and high CPIC levels of evidence (A or B). The final list of medications to collect 




Patient demographics, clinical information, and medication use were abstracted from EPIC, the 
electronic medical record. Medication information was collected at discharge and at the first follow-up 
clinic visit or hospitalization after the catheterization procedure and subsequently documented as 
nominal (yes/no) variables at each time point.  
Outcome measures 
The primary endpoint was the projected number of genotype-guided interventions in the study 
population at discharge or first follow-up that could have occurred if genotype information was available 
at the time of patient encounter. Secondary endpoints included the distribution of total interventions by 
gene in the study population, and the projected annual number of genotype-guided interventions at 
discharge or first follow-up in the UNC catheterization laboratory patient population. 
Calculations and analysis 
Drug prevalence at discharge or first follow-up was calculated using descriptive statistics. Projected 
genotype frequencies for 7 genes at risk for actionable pharmacogenetic recommendations (HLA-B, 
CYP2C19, CYP2D6, CYP2C9, SLCO1B1, VKORC1/CYP2C9, and DYPD) were estimated based on published 
literature for Caucasian-dominated populations from CPIC supplements5,7-13 and, in the case of 
VKORC1/CYP2C9, the ENGAGE AF-TIMI 48 study.12 When only a genotype frequency range was provided 
for CYP2D6 genetic variants and DYPD  partial DPD deficiency, the upper and lower bounds of the 
genotype frequency were averaged.10,13 The Hardy-Weinberg equation was used to calculate at risk 
genotype frequencies when only allele frequencies were available, such as in the case of SLCO1B1 C and 
HLA-B*1502 allele carriers.8,11 The projected number of interventions for each drug was calculated by 
multiplying the observed drug frequency, projected at risk genotype frequency, and number of patients 
in the study population. The overall number of interventions was summed (see Table 4). 
Results 
A population of 183 patients from the UNC Cardiac Catheterization Laboratory who had donated blood 
samples to the biorepository were screened for inclusion. Forty-seven patients either had no follow-up 
in the UNC system or did not have medication records listed in their patient charts and were excluded 
from the analysis. An additional fourteen patients did not meet eligibility due to their first follow-up visit 
being greater than 180 days (see Figure 1). 
Patient demographics 
The study population included 122 patients who had a first follow-up clinic visit or hospitalization within 
180 days of the catheterization procedure. Patients were on average 63 years old, 57% male, and 73% 
Caucasian.  Comorbidities included obesity (50.8%), history of depression (13.9%), hyperlipidemia 
(63.9%), diabetes (33.6%), heart failure (17.2%), and hypertension (77.9%). Approximately 38% of 
patients underwent a percutaneous coronary intervention during the catheterization procedure and the 




Prevalence of genetically actionable drugs  
The most prevalent genetically actionable drug at discharge or at first follow-up was clopidogrel (59 
patients; 48.4%), followed by antidepressants (25 patients; 20.5%), simvastatin (17 patients; 13.9%), and 
warfarin (11 patients; 9.0%). Genetically actionable drugs with lower prevalence included allopurinol (3 
patients; 2.5%), phenytoin (2 patients; 1.6%), and codeine (2 patients; 1.6%). No patients were on 
carbamazepine and fluorouracil either at discharge or at first follow-up (see Table 2). 
At risk genotype frequencies 
Corresponding at-risk genotypes of interest and projected Caucasian frequencies for the most prevalent 
genetically actionable drug at discharge or at first follow-up were CYP2C19 intermediate or poor 
metabolizers (28.9%) for clopidogrel, CYP2C19 ultra-rapid or poor metabolizers (32.5%) for 
antidepressants, SLCO1B1 C allele carriers (23.6%) for simvastatin, and VKORC1/CYP2C9 sensitive or 
highly sensitive responders (38.3%) for warfarin. The projected Caucasian at-risk genotype frequencies 
for CYP2D6 ultra-rapid, intermediate, or poor metabolizers was 15.5%. The projected Caucasian at-risk 
genotype frequencies for individuals with partial or full DPD deficiency was 4.2%. HLA-B*5801 and HLA-
B*1502 allele carriers had projected Caucasian at-risk genotype frequencies of 0.8% and 0.01% 
respectively (see Table 3). 
Projected genotype-guided interventions in study population 
The total projected number of genotype-guided interventions at discharge or first follow-up in the study 
population was 32. The distribution of total genotype-guided interventions in the study population by 
gene was 71.9% for CYP2C19, 12.5% for SLCO1B1, 12.5% for VKORC1/CYP2C9, and 3.1% for CYP2C9. 
There were no projected interventions involving drugs actionable for CYP2D6, HLA-B, and DYPD. 
Assuming each intervention is unique to one patient, a genotype-guided medication intervention could 
have been made in 26.2% (32 of 122) of the study population within 6 months of their presentation to 
the cardiac catheterization laboratory (see Table 5 and Figure 2). 
Projected annual genotype-guided interventions  
When carried out to the annual UNC Catheterization Laboratory population of 2000 patients, the total 
projected number of genotype-guided interventions at discharge or first follow-up increased to 565. A 
total of 396 interventions involved CYP2C19 drugs, 11 involved CYP2C9, 66 involved SLCO1B1, 69 
involved VKORC1/CYP2C9 and 23 involved CYP2D6 drugs. The discretion between the number of 
projected CYP2D6 genotype-guided interventions in the study population and the annual catheterization 
laboratory patients can be attributed to the how the interventions were calculated. Before the total 
number of interventions was summed, the calculated interventions were rounded as such: calculated 
intervention of greater than or equal to 0.5 was rounded up to 1 and calculated intervention less than 
0.5 was rounded down to 0. With a higher patient population, the calculated CYP2D6 related 
interventions that was originally rounded down are now showing up (see Table 6). 
Discussion  
This study found that a preemptive genotyping strategy in cardiac catheterization laboratory patients 
would result in a genotype-guided intervention in approximately 1 out of every 4 patients within 6 
months of their presentation to the catheterization laboratory, which could optimize medication use in 
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accordance with FDA boxed warnings and CPIC guideline recommendations. We arbitrarily chose the 6 
month time window for our analysis as a means of estimating the immediate number of genotype-
guided interventions that could be made. The high prevalence of genetically actionable drugs during this 
short period of time serves as compelling evidence to implement pharmacogenomic testing in this 
population. Additionally, as almost 30% of interventions involved non-CYP2C19 drugs, the potential 
benefit of a multi-gene panel that extends far beyond just CYP2C19 testing.  
One of the study’s limitations was it’s a small sample size, which puts the generalizability of the results 
into question. However, the characteristics of cohort of patients are comparable to that of the general 
catheterization laboratory population, according to patient data for 2014 that was reported in four 
National Cardiovascular Data Registries.15 Actionable oncology and immunomodulatory drugs were not 
assessed in this study per the patient exclusion criteria, due to the complexity of treatment regimens in 
patients with active cancers or inflammatory conditions. Thus, the results of this study should not be 
applied to this patient subset. Additionally, this study assumed that medication changes will occur given 
the presence of an at-risk genotype regardless of other clinical factors, which oftentimes does not 
happen in clinical practice as treatment is dependent on a multimodal approach that is specific to the 
patient.  
Another limitation of the study was that the projected number of genotype-guided interventions was 
calculated based on publicly available Caucasian at-risk genotype frequencies which does not take into 
account genetic variances between ethnic groups. For example, African Americans have a higher 
probability of carrying a CYP2C19 loss-of-function variant allele than Caucasians, and African Americans 
made up approximately 21.3% of our study population.9 The failure to account for a multiethnic 
population was due to the difficulty of accurately estimating at-risk genotype frequencies from publicly 
available data. However, this study only serves as phase one of a two-phase study. Patients were 
required to donate blood samples to the biorepository to be considered for inclusion. In the subsequent 
phase, their genetic samples will be preemptively genotyped using a multi-gene panel developed by Tim 
Wiltshire’s laboratory at the UNC Eshelman School of Pharmacy. This will allow us to determine the 
actual number of immediate genotype-guided interventions that could be made in this catheterization 
laboratory study population. 
We took a very conservative approach in this study to project the genetically-guided interventions in this 
patient population. We defined a drug as genetically actionable if they had FDA boxed warnings and/or 
CPIC guidelines that recommended a specific action. However, there are numerous more medications 
that have pharmacogenomic information in their FDA labelling that are common to the cardiac 
catheterization laboratory population, such as anti-diabetic agents, proton pump inhibitors, and heart 
failure drugs.2, 15 Current genomic information on these agents is limited, with data only providing 
implications on clinical pharmacology and adverse reactions. However, as more pharmacogenomic data 
is published, there may be actionable genetically-guided recommendations developed for these drugs, 
and the number of possible genotype-guided interventions in this population would subsequently 
increase. Additionally, we only assessed the interventions that could be made within a 6 month period. 
During the study, it was observed that a significant number of patients were either switched to or 
initiated on genetically actionable medications beyond the 6 month time frame, although this 
phenomenon was not formally assessed.  
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The determination of the clinical benefits from preemptive genotyping in patients earlier on may lead to 
a considerable decrease in risk of adverse events, hospital admissions, and cost of medical care for the 
patient and institution. Several studies have been published supporting the use of a preemptive 
genotyping strategy in patients. Van Driest S, et al. looked at 9,589 individuals who had undergone 
preemptive pharmacogenomic testing through the Vanderbilt Pharmacogenomic Resource for Enhanced 
Decisions in Care and Treatment (PREDICT) program. The panel-based test identified one or more 
actionable variants in 91% of the genotyped patients. Using medication exposure data from electronic 
medical records, the study theorized that reactive genotyping would have generated 14,656 genetic 
tests.16 Schildcrout J, et al. examined the prescription frequency of 56 medications with known 
outcomes influenced by variant alleles in a cohort of 52,942 medical home patients at Vanderbilt 
University Medical Center (VUMC). The study found that within 5 years, 64.8% of individuals were 
exposed to at least one medication with an established pharmacogenetic association. Additionally, the 
study estimated that 383 events, attributed to six medications with severe, well-characterized, 
genetically linked adverse events, could have been prevented with an effective preemptive genotyping 
program.17  
To our knowledge, our study is the first-of-its-kind in evaluating the use of a preemptive genotyping 
strategy in cardiac catheterization laboratory patients. A significant barrier to the widespread 
implementation of pharmacogenomic-guided medication therapy is the absence of a clearly defined 
target population. The results of this study provide evidence that cardiac catheterization patients are a 
promising target population that may benefit from a preemptive, panel-based genotyping strategy. 
Although additional analyses are required to determine whether preemptive genotyping should be 
implemented in cardiac catheterization patients, this study serves as a guide for future research that 
assess the impact of preemptive genotyping on outcomes and cost, and ultimately, establishing 
preemptive genotyping as an essential and wide-spread testing methodology that can lead to significant 
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183 patients referred for 




14 had >180 day follow-up 
47 had no follow-up or a 
documented medication list
Figure 1: Flow diagram of eligibility 
7 had no follow-up or no 
documented medication list 
14 had >180 day follow-up 
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Demographics 
Age (Mean ± SDa) 62.8 ± 10.4 
Male 69 (56.6%) 
Caucasian 89 (73.0%) 
Comorbidities 
Obese (BMIb ≥30) 62 (50.8%) 
Depression 17 (13.9%) 
Hyperlipidemia 78 (63.9%) 
Diabetes 41 (33.6%) 
Hypertension 95 (77.9%) 
Heart failure 21 (17.2%) 
CAD History 
Previous MIc 22 (18.0%) 
Prior PCId 37 (30.3%) 
PCI during index visit 46 (37.7%) 
Days to first follow-up 
visit (Mean ± SD) 
35.9 ± 34.5 
Footnote: 
a. Standard deviation
b. Body mass index
c. Myocardial infarction
d. Percutaneous coronary intervention
Table 1: Baseline characteristics 
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Drug Prevalence (n) 
Amitriptyline 3.3% (4) 
Citalopram 6.6% (8) 
Clomipramine 0% (0) 
Desipramine 0.8% (1) 
Doxepin 0% (0) 
Escitalopram 1.6% (2) 
Fluvoxamine 0% (0) 
Imipramine 0.8% (1) 
Nortriptyline 0% (0) 
Paroxetine 2.5% (3) 
Sertraline 4.9% (6) 
Trimipramine 0% (0) 
Total Antidepressants 20.5% (25) 
Carbamazepine 0% (0) 
Phenytoin 1.6% (2) 
Total Anticonvulsants 1.6% (2) 
Allopurinol 2.5% (3) 
Clopidogrel 48.4% (59) 
Codeine 1.6% (2) 
Simvastatin 13.9% (17) 
Warfarin 9.0% (11) 
Fluorouracil 0% (0) 
Table 2: Actionable drug prevalence at 






















































T/C genotype 21.6% Simvastatin 













DPD deficiency 0.2% Fluorouracil 
Table 3: Projected at-risk Caucasian genotype frequencies 
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Drug Biomarker Referenced 
subgroup(s) 
Drug prevalence 








Clopidogrel CYP2C19 CYP2C19 
intermediate and 
poor metabolizers 
48.4% 28.9% 17e 
Warfarin CYP2C9/VKORC1 Sensitive/highly 
sensitive 
responders 
9.0% 38.3% 4 
Simvastatin SLCO1B1 C allele carriers 13.9% 23.6% 4 
Study population (n=122) 
Biomarker Discharge First Follow-Up Discharge or First Follow-Up 
HLA-B 0 (0.0%) 0 (0.0%) 0 (0.0%) 
CYP2D6 0 (0.0%) 0 (0.0%) 0 (0.0%) 
CYP2C19 17 (73.9%) 22 (71.0%) 23 (71.9%) 
CYP2C9 1 (4.3%) 1 (3.2%) 1 (3.1%) 
SLCO1B1 3 (13.0%) 4 (12.9%) 4 (12.5%) 
VKORC1/CYP2C9 2 (8.7%) 4 (12.9%) 4 (12.5%) 
Total 23 (100.0%) 31 (100.0%) 32 (100.0%) 
Figure 2: Distribution of total interventions by gene in 
study population 
Footnote: 
e. Calculation: 0.484*0.289*122 = 17 
Table 5: Projected number of interventions at discharge or first follow-up in study population 
Table 4: Sample calculation 
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Annual UNC catheterization laboratory population (n=2000) 
Biomarker First Follow-Up Discharge or First Follow-Up 
HLA-B 0 (0.0%) 0 (0.0%) 
CYP2D6 25 (4.6%) 25 (4.4%) 
CYP2C19 382 (69.7%) 396 (69.7%) 
CYP2C9 12 (2.2%) 12 (2.1%) 
SLCO1B1 66 (12.0%) 66 (11.6%) 
VKORC1/CYP2C9 63 (11.5%) 69 (12.1%) 
Total 548 (100.0%) 568 (100.0%) 
Table 6: Projected annual number of interventions at discharge or first follow-up 
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Drug Biomarker(s) Referenced Subgroup(s) FDA Labeling Change FDA Blackbox Warning(s) CPIC Guidelines
Top 200 Prescribed in 2012 
(Y/N); Rank(s)
Top 200 Sold  ($) in 2012 
(Y/N); Rank(s)
Abacavir HLA-B HLA-B*5701 allele carriers
Contraindications, Warnings and 
Precautions 
Hypersensitivity reactions: Increased risk for serious to 
fatal hypersensitivity reactions in HLA-B*5701 allele 
carriers. Screening for allele prior to therapy initiation is 
recommended. Yes (2012 and 2014)  No No
Allopurinol HLA-B HLA-B*5801 allele carriers No No Yes (2013 and 2015) Yes; 123, 194 No
Amitriptyline CYP2D6 CYP2D6 poor metabolizers Precautions No Yes (2013) Yes; 134 No
CYP2C19 CYP2C19 poor metabolizers No No Yes (2013)  
Arformoterol UGT1A1 UGT1A1 poor metabolizers Clinical Pharmacology No No No No
CYP2D6
CYP2D6 intermediate or poor 
metabolizers Clinical Pharmacology No No
Aripiprazole CYP2D6 CYP2D6 poor metabolizers
Dosage and Administration, Clinical 
Pharmacology No No Yes; 92 Yes; 2
Atomoxetine CYP2D6 CYP2D6 poor metabolizers
Dosage and Administration, Warnings 
and Precautions, Drug Interactions, 
Clinical Pharmacology No No No Yes; 118
Azathioprine TPMT
TPMT intermediate or poor 
metabolizers
Clinical 
Pharmacology, Warnings, Precautions, 
Drug Interactions, Adverse Reactions, 
Dosage and Administration No Yes (2011 and 2013) No No
Boceprevir IFNL3
IL28B rs12979860 T allele 
carriers (C/T and T/T genotype) Clinical Pharmacology No Yes (2013) No No
Carbamazepine HLA-B HLA-B*1502 allele carriers Boxed Warning, Warnings, Precautions
Dermatological reactions: Increased risk for serious to 
fatal dermatological reactions, including toxic epidermal 
necrolysis and Stevens-Johnson syndrome, in HLA-
B*1502 allele carriers. This allele is almost found 
exclusively in patients with Asian ancestry. Screen 
genetically at-risk populations prior to therapy initiation 
and do not treat allele-positive patients unless benefit 
clearly outweighs risk. Yes (2013) No No




Indications and Usage, Warnings and 
Precautions, Use in Specific Populations, 
Clinical Pharmacology, Clinical Studies No No No No
Carisoprodol CYP2C19 CYP2C19 poor metabolizers
Use in Specific Populations, Clinical 
Pharmacology No No No No
Carvedilol CYP2D6 CYP2D6 poor metabolizers Drug Interactions, Clinical Pharmacology No No Yes; 86, 142 No
Celecoxib CYP2C9 CYP2C9 poor metabolizers
Dosage and Administration, Use in 
Specific Populations, Clinical 
Pharmacology No No Yes; 76 Yes; 26
Cevimeline CYP2D6 CYP2D6 poor metabolizers Precautions No No No No
Chloroquine G6PD G6PD deficient Precautions No No No No
Chlorpropamide G6PD G6PD deficient Precautions No No No No
Citalopram CYP2C19 CYP2C19 poor metabolizers
Clinical Pharmacology, Warnings, Dosage 
and Administration Yes (2015) Yes; 64, 81 No
Clobazam CYP2C19 CYP2C19 poor metabolizers
Dosage and Administration, Use in 
Specific Populations, Clinical 
Pharmacology No No No No
Clomipramine CYP2D6 CYP2D6 poor metabolizers Precautions No Yes (2013) No No
CYP2C19 CYP2C19 poor metabolizers No No Yes (2013)
Table 7: Drugs with Pharmacogenomic information in FDA labeling
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Clopidogrel CYP2C19
CYP2C19 intermediate or poor 
metabolizers
Boxed Warning, Dosage and 
Administration, Warnings and 
Precautions, Clinical Pharmacology
Diminished effectiveness: Diminished effect of 
clopidogrel on platelet function in CYP2C19 poor 
metabolizers and exhibition of higher cardiovascular 
event rates in poor metabolizers who also have acute 
coronary syndrome or who are undergoing 
percutaneous coronary intervention as compared to 
normal metabolizers. Consider alternative treatment or 
treatment strategies in poor metabolizers. Yes (2011 and 2013) Yes; 55 Yes; 13
Clozapine CYP2D6 CYP2D6 poor metabolizers
Dosage and Administration, Use in 
Specific Populations, Clinical 
Pharmacology No No No No
Codeine CYP2D6 CYP2D6 ultra-rapid metabolizers
Boxed Warnings, Warnings and 
Precautions, Use in Specific Populations, 
Patient Counseling Information
Ultra-rapid metabolism of codeine to morphine: 
Occurrence of respiratory depression and death in 
children receiving codeine after tonsillectomy and/or 
adenoidectomy with evidence of being a CYP2D6 ultra-
rapid metabolizer. Yes (2012 and 2014)  No No
Dapsone G6PD G6PD deficient
Warnings and Precautions, Use in 
Specific Populations, Patient Counseling 
Information, Adverse Reactions, 
Overdosage No No No No
Darifenacin CYP2D6 CYP2D6 poor metabolizers Drug Interactions, Clinical Pharmacology No No No No
Desipramine CYP2D6 CYP2D6 poor metabolizers Precautions No Yes (2013) No No
CYP2C19 CYP2C19 poor metabolizers No No Yes (2013)
Dexlansoprazole CYP2C19 CYP2C19 poor metabolizers Drug Interactions, Clinical Pharmacology No No Yes; 182 Yes; 80
Dextromethorphan 
quinidine CYP2D6 CYP2D6 poor metabolizers
Warnings and Precautions, 
Clinical Pharmacology No No No No
Diazepam CYP2C19 CYP2C19 poor metabolizers Clinical Pharmacology No No Yes; 122, 196 No
Divalproex POLG POLG mutation positive
Boxed Warning, Contraindications, 
Warnings and Precautions 
Acute liver failure: Increased risk of valproate-induced 
hepatic failure and deaths in patients with hereditary 
neurometabolic syndromes caused by DNA mutations 
of the mitochondrial DNA polymerase gamma (POLG) 
gene (eg, Alpers-Huttenlocher syndrome). Use is 
contraindicated in patients with mitochondrial 
disorders caused by POLG mutations and children <2 
years with suspected POLG-related disorder. In patients 
≥2 years with suspected POLG-related disorder, only 
use after failure of other anticonvulsants with close 
monitoring for acute liver injury. Conduct POLG 
mutation screening in accordance with current clinical 
practice.
No No No
Doxepin CYP2D6 CYP2D6 poor metabolizers Clinical Pharmacology Yes (2013) No No




metabolizers Clinical Pharmacology No No No
Eliglustat CYP2D6
CYP2D6 ultrarapid, intermediate 
or poor metabolizers
Indications and Usage, Dosage and 
Administration, Contraindications, 
Warnings and Precautions, Drug 
Interactions, Use in Specific 
Populations, Drug Interactions, Use in 
Specific Populations, Clinical 
Pharmacology, Clinical Studies No No No No
Eltrombopag F5 Factor V Leiden carriers Warnings and Precautions No No No
SERPINC1 Antithrombin III deficient Warnings and Precautions No No No
Erythromycin/Sulfis
oxazole G6PD G6PD deficient Warnings and Precautions No No No No
Esomeprazole CYP2C19 CYP2C19 poor metabolizers Drug Interactions, Clinical Pharmacology No Yes; 12** Yes; 1**
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Escitalopram CYP2C19 CYP2C19 poor metabolizers No No Yes (2015) Yes; 72, 128, 153 Yes; 81, 113, 136
Fesoterodine CYP2D6 CYP2D6 poor metabolizers Drug Interactions, Clinical Pharmacology No No No No
Fluorouracil DPYD DPD deficient
Contraindications, Warnings, Patient 
Information No Yes (2014, 2013) No No
Fluoxetine CYP2D6 CYP2D6 poor metabolizers
Clinical Pharmacology, 
Warnings, Precautions No No Yes; 57 No
Flurbiprofen CYP2C9 CYP2C9 poor metabolizers Clinical Pharmacology No No No No
Fluvoxamine CYP2D6 CYP2D6 poor metabolizers Drug Interactions No Yes (2015) No No
Galantamine CYP2D6 CYP2D6 poor metabolizers Clinical Pharmacology No No No No
Glimepiride G6PD G6PD deficient
Warning and Precautions, Adverse 
Reactions No No No No
Glipizide G6PD G6PD deficient Precautions No No No No
Glyburide G6PD G6PD deficient Precautions No No No No
Iloperidone CYP2D6 CYP2D6 poor metabolizers
Dosage and Administration, Warnings 
and Precautions,Drug Interactions, 
Clinical Pharmacology No No No No
Imipramine CYP2D6 CYP2D6 poor metabolizers Precautions No Yes (2013) No No
CYP2C19 CYP2C19 poor metabolizers No No Yes (2013) No No
Indacaterol UGT1A1 UGT1A1-*28 allele homozygotes Clinical Pharmacology No No No No
Isosorbide dinitrate 
and Hydralazine NAT1-2 Slow acetylators Clinical Pharmacology No No No No
Ivacaftor CFTR
CFTR G551D, G1244E, G1349D, 
G178R, G551S, S1251N, S1255P, 
S549N, or S549R mutation 




Use in Specific Populations
Clinical Pharmacology
Clinical Studies No Yes (2014) No No
Lansoprazole CYP2C19
CYP2C19 intermediate or poor 




Boxed Warning, Indications and Usage,
Adverse Reactions, Use in Specific 
Populations, 
Clinical Studies
Hematologic toxicity (grade 3/4): Lenalidomide can 
cause neutropenia and thrombocytopenia in 80% of 
patients with del 5q myelodysplastic syndrome. May 
require dose reductions and/or delays. Monitor CBC 
weekly for first 8 weeks and at least monthly thereafter 
in patients being treated for del 5q myelodysplastic 
syndromes. Use of blood product support and/or 
growth factors may be needed. No No Yes; 120
Lomitapide LDLR
LDLR mutation homozygotes 
(homozygous familial 
hypercholesterolemia) 
Indication and Usage, Warnings and 
Precautions, Adverse Reactions, Clinical 
Studies No No No No
Mafenide G6PD G6PD deficient
Warnings
Adverse Reactions No No No No
Methylene blue G6PD G6PD deficient Precautions No No No No
Metoclopramide CYB5R1-4
NADH cytochrome b5 
reductase deficient Precautions No No No No
Metoprolol CYP2D6
CYP2D6 poor 
metabolizers Clinical Pharmacology No No Yes; 16, 32, 69 106, 183, 186  Yes; 145
Mipomersen LDLR
LDLR mutation heterozygotes 
and homozygotes 
(heterozygous and homozygous 
familial hypercholesterolemia)
Boxed Warning, Indications and Usage, 
Warnings and Precautions, 
Adverse Reactions, Use in Specific 
Populations, Clinical Studies
Transaminase elevation: In clinical trials in patients with 
homozygous familial hypercholesterolemia, 12% of 
patients treated with mipomersen had at least 1 
elevation in ALT at least 3 times the upper limit of 
normal (ULN); Increase in hepatic fat with or without 
concomitant transaminase elevations: In trials in 
patients with heterozygous familial 
hypercholesterolemia and hyperlipidemia, the median 
absolute increase in hepatic fat was 10% (from 0% at 
baseline) after 26 weeks of treatment. Hepatic steatosis 
is a risk factor for advanced liver disease, including 




metabolizers Clinical Pharmacology, Precautions No No No Yes; 137
Mycophenolic Acid HPRT1 HGPRT deficient Warnings and Precautions No No No No
Nalidixic Acid G6PD G6PD deficient Precautions, Adverse Reactions No No No No
Nefazodone CYP2D6
CYP2D6 poor 
metabolizers Precautions No No No No
Nitrofurantoin G6PD G6PD deficient
Warnings,
Adverse Reactions No No No No
Norfloxacin G6PD G6PD deficient Precautions, Adverse Reactions No No No No
Nortriptyline CYP2D6
CYP2D6 poor 
metabolizers Precautions No Yes (2013) No No
Omeprazole CYP2C19
CYP2C19 poor 
metabolizers Drug Interactions No No Yes; 28, 29, 45, 46, 131** No**
Pantoprazole CYP2C19
CYP2C19 poor 
metabolizers Clinical Pharmacology No No Yes; 121** No**
Paroxetine CYP2D6
CYP2D6 extensive







(Vitamin C) G6PD G6PD deficient Warnings and Precautions No No No** No**
Peginterferon alfa-
2a IFNL3
IL28B rs12979860 T allele 
carriers (C/T and T/T genotype) Clinical Pharmacology, Efficacy No Yes (2013) No No
Peginterferon alfa-
2b IFNL3
IL28B rs12979860 T allele 
carriers (C/T and T/T genotype) Clinical Pharmacology, Efficacy No Yes (2013) No No
Pegloticase G6PD G6PD deficient
Contraindications





Precautions No No No No
Phenytoin HLA-B
HLA-B*1502 
allele carriers Warnings No Yes (2014) No No










metabolizers No No No Yes; 184
CYP2C9 CYP2C9 variant carriers
Use in Specific Populations
Clinical Pharmacology
Clinical Studies No No
CYP3A5 CYP3A5 variant carriers
Use in Specific Populations
Clinical Pharmacology
Clinical Studies No No
CYP2B6 CYP2B6 variant carriers
Use in Specific Populations
Clinical Pharmacology
Clinical Studies No No
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Pravastatin LDLR
LDLR mutation heterozygotes 
and homozygotes (heterozygous 
and homozygous familial 
hypercholesterolemia)
Indications and Usage, 
Use in Specific Populations, 
Clinical Studies
No No Yes; 25, 136 No
Primaquine G6PD G6PD deficient
Warnings, Precautions, 
Adverse Reactions No No No No




Dosage and Administration, 
Warnings and Precautions, 
Clinical Pharmacology No No No No
Propranolol CYP2D6
CYP2D6 poor 
metabolizers Clinical Pharmacology No No No No
Protriptyline CYP2D6
CYP2D6 poor 
metabolizers Precautions No No No No
Quinidine CYP2D6
CYP2D6 poor 
metabolizers Precautions No No No No
Quinine Sulfate G6PD G6PD deficient Contraindications No No No No





Clinical Pharmacology No No No Yes; 69
Rifampin, Isoniazid, 
and Pyrazinamide NAT1-2 Slow acetylators (inactivators)
Clinical Pharmacology, 
Adverse Reactions No No No No
Risperidone CYP2D6
CYP2D6 poor 
metabolizers Clinical Pharmacology No No Yes; 138 Yes; 141
Ribaviran IFNL3
IL28B rs12979860 T allele 
carriers (C/T and T/T genotype) No No Yes (2013) No No
Sertraline CYP2C19 CYP2C19 poor metabolizers No No Yes (2015) Yes; 36, 54, 79 No
Simeprevir IFNL3
IL28B rs12979860 T allele 
carriers Clinical Pharmacology, Clinical Studies No No No No
Simvastatin SLCO1B1
rs4149056 C allele carriers (T/C 
and C/C genotype) No No Yes (2012 and 2014)  
Yes; 6, 42, 58, 63, 85, 140, 
141 No






ASL, ABL2 Urea cycle enzyme deficient
Indications and Usage, Dosage and 
Administration, Warnings and 
Precautions, Adverse Reactions, Drug 
Interactions, Use in Specific Populations, 
Overdosage, Clinical Pharmacology, 
Clinical Studies No No No No
Sofosbuvir IFNL3
IL28B rs12979860 T allele 
carriers (non-C/C genotype)IL28B Clinical Studies No No No No
Succimer G6PD G6PD deficient Clinical Pharmacology No No No No
Succinylcholine BCHE Atypical homozygous carriers
Adverse Reactions, Warnings and 
Precautions No No No No
Sulfadiazine G6PD G6PD deficient Warnings No No No No
Sulfamethoxazole/T
rimethoprim G6PD G6PD deficient Precautions No No No No
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Sulfasalazine G6PD G6PD deficient Precautions No No No No
Tacrolimus CYP3A5
CYP3A5 intermediate or 
extensive metabolizers No No Yes (2015) No Yes; 165
Telaprevir IFNL3
IL28B rs12979860 T allele 
carriers (C/T and T/T genotype) Clinical Pharmacology, Clinical Studies No Yes (2013) No Yes; 39
Terbinafine CYP2D6
CYP2D6 poor 




Dosage and Administration, Warnings 
and Precautions, Use in Specific 
Populations, Clinical Pharmacology No No No No
Thioridazine CYP2D6
CYP2D6 poor 
metabolizers Contraindications, Warnings, Precautions No No No No
Ticagrelor CYP2C19
CYP2C19 poor 
metabolizers Clinical Studies No No No No
Tolterodine CYP2D6 CYP2D6 poor metabolizers
Warnings and Precautions, Drug 
Interactions, Use in Specific Populations, 
Clinical Pharmacology No No No Yes; 108
Tramadol CYP2D6
CYP2D6 poor 
metabolizers Clinical Pharmacology No No Yes; 52, 83, 88 No
Trimipramine CYP2D6
CYP2D6 poor 
metabolizers Precautions No Yes (2013) No No
CYP2C19
CYP2C19 ultrarapid and poor 







Acute liver failure: Increased risk of valproate-induced 
hepatic failure and deaths in patients with hereditary 
neurometabolic syndromes caused by DNA mutations 
of the mitochondrial DNA polymerase gamma (POLG) 
gene (eg, Alpers-Huttenlocher syndrome). Use is 
contraindicated in patients with mitochondrial 
disorders caused by POLG mutations and children <2 
years with suspected POLG-related disorder. In patients 
≥2 years with suspected POLG-related disorder, only 
use after failure of other anticonvulsants with close 
monitoring for acute liver injury. Conduct POLG 










Warnings and Precautions No No
Venlafaxine CYP2D6
CYP2D6 poor 
metabolizers Precautions No No Yes; 90 No
Voriconazole CYP2C19
CYP2C19 intermediate or
poor metabolizers Clinical Pharmacology No No No No
Vortioxetine CYP2D6 CYP2D6 poor metabolizers
Dosage and Administration,






Clinical Pharmacology No Yes (2011 and 2013) Yes; 18, 89 No
VKORC1 VKORC1 A allele carriers
Dosage and Administration
Clinical Pharmacology No Yes (2011 and 2013)
PROS Protein S deficient Warnings and Precautions No No
PROC Protein C deficient Warnings and Precautions No No
**OTC Options 
Available and not 
accounted for
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